RegeneRx Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for tissue repair and regeneration. The company’s work centers on Thymosin Beta 4 (Tβ4), a naturally occurring peptide that plays a key role in cellular migration, angiogenesis and wound healing. RegeneRx leverages its Tβ4 platform to advance treatments for a range of acute and chronic conditions in ophthalmology, dermatology, cardiology and neurology.
The company’s lead therapeutic candidate, RGN-259, is a topical formulation of Tβ4 that has been studied in clinical trials for dry eye syndrome and various dermatological indications, including epidermolysis bullosa. Additional pipeline candidates include RGN-352, an injectable form of Tβ4 for myocardial infarction and ischemic injury, and RGN-3479 for central nervous system repair. RegeneRx also explores complementary peptides for applications in inflammation, fibrosis and tissue remodeling.
Founded in 1995 and headquartered in Rockville, Maryland, RegeneRx has built a foundation of intellectual property around its Tβ4 platform, with worldwide patents and patent applications. The company has collaborated with academic institutions such as the University of Pittsburgh and formed strategic partnerships in Asia to support preclinical research and clinical development. These alliances aim to accelerate regulatory filings and eventual commercialization in key markets across North America, Europe and Asia.
Under the leadership of President and Chief Executive Officer Patrick C. Harned, RegeneRx’s management team includes professionals with extensive experience in drug development, regulatory affairs and corporate strategy. The board of directors brings additional expertise from the biotechnology and pharmaceutical industries, guiding the company’s efforts to translate its peptide-based science into meaningful therapies for patients worldwide.
AI Generated. May Contain Errors.
